Corporate News

2024 – Adjuvancy effects of a RIG-I agonist (RIG-101) on H1N1 HA antigen intranasally vaccinated mice and human nasal epithelium/PBMCs co-culture

2024 – Pan-antiviral effects of RIG-I agonist (RIG101) against respiratory syncytial virus and human rhinovirus in nasal epithelium in vitro and mice in vivo

2024 – Effects of an anti-viral interferon booster, RIG-I agonist (RIG-101), on influenza infection in vitro and in vivo

2024 – Targeted non-LNP Delivery of RNA Therapeutics

2024 – RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024 

2023 – Pyle is Elected to National Academy of Sciences

2022 – RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments

2022 – RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital

2023 – A rapid RIG-I signaling relay mediates efficient antiviral response

2022 – The RIG-I receptor adopts two different conformations for distinguishing host from viral RNA ligands

2021 – The molecular mechanism of RIG-I activation and signaling

2021 – A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice

2019 – Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses

2014 – Parts, assembly and operation of the RIG-I family of motors

2014 – Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma

2013 – Defining the functional determinants for RNA surveillance by RIG-I

2011 – Structural Insights into RNA Recognition by RIG-I

2002 – mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties